This systematic review included 11 studies involving 2895 patients comparing MAP targets in septic shock. Across three trials, 90-day mortality was 44.4% with elevated targets versus 38.8% with lower targets (OR 1.31, 95% CI 0.97-1.77), without a statistically significant difference. Renal findings were inconsistent; elevated targets increased vasopressor exposure and were associated with more arrhythmias and fewer organ support-free days. No study reported splanchnic ischemia as a discrete outcome, mesenteric ischemia rates were low and similar between groups, and overall evidence certainty was very low.
Elevated MAP targets showed no clear mortality benefit in septic shock. The findings raise concern about greater treatment burden, but very low certainty limits conclusions about benefit or harm.
Study limitation: Overall evidence certainty was very low, and no study reported splanchnic ischemia as a discrete outcome.
AI-generated from the published abstract with automated source checks. For research discovery; consult the original paper before applying findings.